Metabolic and body composition effects of newer antiretrovirals in HIV-infected patients

European Journal of Endocrinology

Volumn 170, Issue 5, 2014, Pages

  Srinivasa, Suman ^a   Grinspoon, Steven K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; DARUNAVIR; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS RILPIVIRINE PLUS TENOFOVIR DISOPROXIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MARAVIROC; RALTEGRAVIR; TRIACYLGLYCEROL;

ATHEROSCLEROTIC PLAQUE; BODY COMPOSITION; CHOLESTEROL BLOOD LEVEL; COMBINATION CHEMOTHERAPY; DRUG MECHANISM; DRUG TARGETING; DRUG USE; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; GLUCOSE HOMEOSTASIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFE CYCLE; LIPODYSTROPHY; METABOLIC DISORDER; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ATHEROSCLEROSIS; BODY COMPOSITION; HIV; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM;

EID: 84899765820     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-13-0967     Document Type: Review

References (113)

1. Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, Riddler SA, Visscher BR, Margolick JB & Dobs AS. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Archives of Internal Medicine 2005 165 1179-1184. (doi:10.1001/archinte.165.10.1179
2. Brown TT, Li X, Cole SR, Kingsley LA, Palella FJ, Riddler SA, Chmiel JS, Visscher BR, Margolick JB & Dobs AS. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS 2005 19 1375-1383. (doi:10.1097/01.aids.0000181011.62385.91
3. Walli R, Herfort O, Michl GM, Demant T, Jager H, Dieterle C, Bogner JR, Landgraf R & Goebel FD. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998 12 F167-F173. (doi:10.1097/00002030- 199815000-00001
4. Mallon PW, Miller J, Cooper DA & Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 2003 17 971-979. (doi:10.1097/00002030-200305020-00005
5. Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, Thiebaut R, De Wit S, Kirk O, Fontas E et al. Class of antiretroviral drugs and the risk of myocardial infarction. New England Journal of Medicine 2007 356 1723-1735. (doi:10.1056/NEJMoa062744
6. Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz N, Davis B, Sax P, Stanley T, Wilson PWet al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clinical Infectious Diseases 2001 32 130-139. (doi:10.1086/317541
7. Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, Palella F, Visscher B, Evans R & Kingsley LA. Impact of HIV infection and HAART on serum lipids in men. Journal of the American Medical Association 2003 289 2978-2982. (doi:10.1001/jama.289.22.2978
8. Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, LawM, Monforte AD, Friis-Moller N et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. Journal of Infectious Diseases 2010 201 318-330. (doi:10.1086/649897
9. Triant VA, Lee H, Hadigan C & Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. Journal of Clinical Endocrinology and Metabolism 2007 92 2506-2512. (doi:10.1210/jc.2006-2190
10. Cote HC. Mechanisms of antiretroviral therapy-induced mitochondrial dysfunction. Current Opinion in HIV and AIDS 2007 2 253-260. (doi:10.1097/COH.0b0REF9=10.1210/jc.2006-2190
11. Fleischman A, Johnsen S, Systrom DM, Hrovat M, Farrar CT, FronteraW, Fitch K, Thomas BJ, Torriani M, Cote HC et al. Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults. American Journal of Physiology. Endocrinology and Metabolism 2007 292 E1666-E1673. (doi:10.1152/ajpendo.00550. 2006
12. Lenhard JM, Furfine ES, Jain RG, Ittoop O, Orband-Miller LA, Blanchard SG, Paulik MA & Weiel JE. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro. Antiviral Research 2000 47 121-129. (doi:10.1016/S0166-3542(00)00102-9
13. Dowell P, Flexner C, Kwiterovich PO & Lane MD. Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors. Journal of Biological Chemistry 2000 275 41325-41332. (doi:10.1074/jbc.M006474200
14. Caron M, Auclair M, Vigouroux C, Glorian M, Forest C & Capeau J. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 2001 50 1378-1388. (doi:10.2337/diabetes. 50.6.1378
15. Murata H, Hruz PW & Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. Journal of Biological Chemistry 2000 275 20251-20254. (doi:10.1074/jbc. C000228200
16. Riddle TM, Kuhel DG, Woollett LA, Fichtenbaum CJ & Hui DY. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. Journal of Biological Chemistry 2001 276 37514-37519. (doi:10.1074/jbc. M104557200
17. den Boer MA, Berbee JF, Reiss P, van der Valk M, Voshol PJ, Kuipers F, Havekes LM, Rensen PC & Romijn JA. Ritonavir impairs lipoprotein lipase-mediated lipolysis and decreases uptake of fatty acids in adipose tissue. Arteriosclerosis, Thrombosis, and Vascular Biology 2006 26 124-129. (doi:10.1161/01.ATV.0000194073.87647.10
18. Krishnan S, Schouten JT, Atkinson B, Brown T, Wohl D, McComsey GA, Glesby MJ, Shikuma C, Haubrich R, Tebas P et al. Metabolic syndrome before and after initiation of antiretroviral therapy in treatment-naive HIV-infected individuals. Journal of Acquired Immune Deficiency Syndromes 2012 61 381-389. (doi:10.1097/QAI.0b013e3182690e3c
19. Phillips AN, Carr A, Neuhaus J, Visnegarwala F, Prineas R, BurmanWJ, Williams I, Drummond F, Duprez D, Belloso WH et al. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antiviral Therapy 2008 13 177-187.
20. Fitch K, Srinivasa S, Abbara S, Burdo TH, Williams KC, Eneh P, Lo J & Grinspoon S. Noncalcified coronary atherosclerotic plaque and immune activation in HIV-infected women. Journal of Infectious Diseases 2013 208 1737-1746. (doi:10.1093/infdis/jit508
21. Aukrust P, Halvorsen B, Yndestad A, Ueland T, Oie E, Otterdal K, Gullestad L & Damas JK. Chemokines and cardiovascular risk. Arteriosclerosis, Thrombosis, and Vascular Biology 2008 28 1909-1919. (doi:10.1161/ATVBAHA.107.161240
22. Szalai C, Duba J, Prohaszka Z, Kalina A, Szabo T, Nagy B, Horvath L & Csaszar A. Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1 K2518 G/G genotype in CAD patients. Atherosclerosis 2001 158 233-239. (doi:10.1016/S0021-9150(01)00423-3
23. Afzal AR, Kiechl S, Daryani YP, Weerasinghe A, Zhang Y, Reindl M, Mayr A, Weger S, Xu Q & Willeit J. Common CCR5-del32 frameshift mutation associated with serum levels of inflammatory markers and cardiovascular disease risk in the Bruneck population. Stroke 2008 39 1972-1978. (doi:10.1161/STROKEAHA.107. 504381
24. Cipriani S, Francisci D, Mencarelli A, Renga B, Schiaroli E, D'Amore C, Baldelli F & Fiorucci S. Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice. Circulation 2013 127 2114-2124. (doi:10.1161/CIRCULATIONAHA.113.001278
25. Kelly K, Queen S, Adams R & Mankowski J. Maraviroc prevents SIV-induced cardiac dysfunction. 19th Conference on Retroviruses and Opportunistic Infections, Seattle, March 5-8, 2012, Abstract 816.
26. Portsmouth S BR, Lazzarin A, Johnson M & Valdez H. Incidence of ischemic cardiovascular events in the maraviroc clinical development program. 10th International Congress on Drug Therapy in HIV Infection, Glasgow, UK. 7-11 November 2010. 2010.
27. MacInnes A, Lazzarin A, Di Perri G, Sierra-Madero JG, Aberg J, Heera J, Rajicic N, Goodrich J, Mayer H & Valdez H. Maraviroc can improve lipid profiles in dyslipidemic patientswith HIV: results from the MERIT trial. HIV Clinical Trials 2011 12 24-36. (doi:10.1310/hct1201-24
28. Funderburg N, Kalinowska M, Eason J, Goodrich J, Heera J, Mayer H, Rajicic N, Valdez H & Lederman MM. Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4C cell rises in HIV-infected patients. PLoS ONE 2010 5 e13188. (doi:10.1371/journal. pone.0013188
29. Hsue P SR, Gilman L, Wu Y, Maka K, Mohammed S, Grunfeld C, Martin J, Deeks S & Hunt P. Effect of maraviroc intensification on endothelial function in treated HIV infection. 19th Conference on Retroviruses and Opportunistic Infections, Seattle, March 5-8, 2012. Abstract 123.
30. Bigoloni A, Gianotti N, Spagnuolo V, Galli L, Nozza S, Cossarini F, Salpietro S, Carini E, Piatti P, Vinci C et al. Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens. AIDS 2012 26 1837-1840. (doi:10.1097/QAD.0b013e32835705dd
31. Murray JM, Emery S, Kelleher AD, Law M, Chen J, Hazuda DJ, Nguyen BY, Teppler H & Cooper DA. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS 2007 21 2315-2321. (doi:10.1097/QAD.0b013e3282f12377
32. Llibre JM, Buzon MJ, Massanella M, Esteve A, Dahl V, Puertas MC, Domingo P, Gatell JM, Larrouse M, Gutierrez M et al. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study. Antiviral Therapy 2012 17 355-364. (doi:10.3851/IMP1917
33. Gandhi RT, Zheng L, Bosch RJ, Chan ES, Margolis DM, Read S, Kallungal B, Palmer S, Medvik K, Lederman MM et al. The effect of raltegravir intensification on low-level residual viremia in HIVinfected patients on antiretroviral therapy: a randomized controlled trial. PLoS Medicine 2010 7. (doi:10.1371/journal.pmed.1000321
34. Huesgen E, Burgos R, Goldstein DA, Max B & Jarrett OD. Severe dyslipidaemia after the addition of raltegravir to a lopinavir/ ritonavircontaining regimen. Antiviral Therapy 2012 17 1385-1388. (doi:10. 3851/IMP2182
35. Martinez E, Larrousse M, Llibre JM, Gutierrez F, Saumoy M, Antela A, Knobel H, Murillas J, Berenguer J, Pich J et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS 2010 24 1697-1707. (doi:10.1097/QAD.0b013e32833a608a
36. Saumoy M, Sanchez-Quesada JL, Martinez E, Llibre JM, Ribera E, Knobel H, Gatell JM, Clotet B, Curran A, Curto J et al. LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudy. Atherosclerosis 2012 225 200-207. (doi:10.1016/j.atherosclerosis.2012.REF40=10.1097/QAI.0b013e3181da1287
37. Boyd MA, Kumarasamy N, Moore CL, Nwizu C, Losso MH, Mohapi L, Martin A, Kerr S, Sohn AH, Teppler H et al. Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study. Lancet 2013 381 2091-2099. (doi:10.1016/S0140-6736(13)61164-2
38. Eron JJ, Young B, Cooper DA, Youle M, Dejesus E, Andrade-Villanueva J, Workman C, Zajdenverg R, Fatkenheuer G, Berger DS et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010 375 396-407. (doi:10.1016/S0140-6736(09)62041-9
39. Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, Berger DS, Zhao J, Xu X, Williams-Diaz A, Rodgers AJ et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009 374 796-806. (doi:10.1016/S0140-6736(09)60918-1
40. Lennox JL, Dejesus E, Berger DS, Lazzarin A, Pollard RB, Ramalho Madruga JV, Zhao J, Wan H, Gilbert CL, Teppler H et al. Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. Journal of Acquired Immune Deficiency Syndromes 2010 55 39-48. (doi:10.1097/QAI.0b013e3181da1287
41. Rockstroh JK, Lennox JL, Dejesus E, Saag MS, Lazzarin A, Wan H, Walker ML, Xu X, Zhao J, Teppler H et al. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clinical Infectious Diseases 2011 53 807-816. (doi:10.1093/cid/cir510
42. Rockstroh JK, DeJesus E, Lennox JL, Yazdanpanah Y, Saag MS, Wan H, Rodgers AJ, Walker ML, Miller M, DiNubile MJ et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. Journal of Acquired Immune Deficiency Syndromes 2013 63 77-85. (doi:10.1097/QAI. 0b013e31828ace69
43. Eron JJ Jr., Rockstroh JK, Reynes J, Andrade-Villanueva J, Ramalho-Madruga JV, Bekker LG, Young B, Katlama C, Gatell-Artigas JM, Arribas JR et al. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infectious Diseases 2011 11 907-915. (doi:10.1016/S1473-3099(11)70196-7
44. Gotuzzo E, Markowitz M, RatanasuwanW, Smith G, Prada G, Morales-Ramirez JO, Strohmaier KM, Lu C, Bhanja S, Nguyen BY et al. Sustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection: final results of a randomized, controlled, phase II study (Protocol 004). Journal of Acquired Immune Deficiency Syndromes 2012 61 73-77. (doi:10.1097/QAI.0b013e318263277e
45. Young B, Vanig T, Dejesus E, Hawkins T, St Clair M, Yau L, Ha B & Shield Study Team . A pilot study of abacavir/lamivudine and raltegravir in antiretroviral-naive HIV-1-infected patients: 48-week results of the SHIELD trial. HIV Clinical Trials 2010 11 260-269. (doi:10.1310/hct1105-260
46. Hatano H, Scherzer R, Wu Y, Harvill K, Maka K, Hoh R, Sinclair E, Palmer S, Martin JN, Busch MP et al. A randomized controlled trial assessing the effects of raltegravir intensification on endothelial function in treated HIV infection. Journal of Acquired Immune Deficiency Syndromes 2012 61 317-325. (doi:10.1097/QAI.0b013e31826e7d0f
47. Masia M, Martinez E, Padilla S, Gatell JM & Gutierrez F. Endothelial function in HIV-infected patients switching from a boosted protease inhibitor-based regimen to raltegravir: a substudy of the SPIRAL study. Journal of Antimicrobial Chemotherapy 2013 68 409-413. (doi:10.1093/jac/dks412
48. Silva EF, Charreau I, Gourmel B, Mourah S, Kalidi I, Guillon B, De Castro N, Caron F, Braun J & Molina JM. Decreases in inflammatory and coagulation biomarkers levels in HIV-infected patients switching from enfuvirtide to raltegravir: ANRS 138 substudy. Journal of Infectious Diseases 2013 208 892-897. (doi:10.1093/infdis/jit280
49. Martinez E, D'Albuquerque PM, Llibre JM, Gutierrez F, Podzamczer D, Antela A, Berenguer J, Domingo P, Moreno X, Perez I et al. Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir. AIDS 2012 26 2315-2326. (doi:10.1097/QAD.0b013e328359f29c
50. Lake J, McComsey G, Hulgan T, Wanke C, Mangili A, Walmsley S, Boger S, Stramotas D & Currier J. Soluble CD14 declines in virologically suppressed women switching from protease inhibitor or NNRTI to raltegravir: the women, integrase, and fat accumulation trial. 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, March 3-6, 2013. Abstract 794.
51. Taiwo B, Matining RM, Zheng L, Lederman MM, Rinaldo CR, Kim PS, Berzins BI, Kuritzkes DR, Jennings A, Eron JJ Jr. et al. Associations of T cell activation and inflammatory biomarkers with virological response to darunavir/ritonavir plus raltegravir therapy. Journal of Antimicrobial Chemotherapy 2013 68 1857-1861. (doi:10.1093/jac/dkt120
52. Pallikkuth S, Fischl MA & Pahwa S. Combination antiretroviral therapy with raltegravir leads to rapid immunologic reconstitution in treatment-naive patients with chronic HIV infection. Journal of Infectious Diseases 2013 208 1613-1623. (doi:10.1093/infdis/jit387
53. Ceccarelli G, d'Ettorre G, Marchetti F, Rizza C, Mastroianni CM, Carlesimo B & Vullo V. Development of Buffalo Hump in the course of antiretroviral therapy including raltegravir and unboosted atazanavir: a case report and review of the literature. Journal of Medical Case Reports 2011 5 70. (doi:10.1186/1752-1947-5-70
54. Ferrer E, del Rio L, Martinez E, Curto J, Domingo P, Ribera E, Negredo E, Rosales J, Saumoy M, Ordonez J et al. Impact of switching from lopinavir/ritonavir to atazanavir/ritonavir on body fat redistribution in virologically suppressed HIV-infected adults. AIDS Research and Human Retroviruses 2011 27 1061-1065. (doi:10.1089/aid. 2010.0254
55. Lake JE, McComsey GA, Hulgan TM, Wanke CA, Mangili A, Walmsley SL, Boger MS, Turner RR, McCreath HE & Currier JS. A randomized trial of Raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophy. AIDS Patient Care and STDS 2012 26 532-540. (doi:10.1089/apc.2012.0135
56. Murphy RL, Berzins B, Zala C, Fichtenbaum C, Dube MP, Guaraldi G, Torriani F, Belsey E, Mitchell C & Stein JH. Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy. AIDS 2010 24 885-890. (doi:10.1097/QAD.0b013e3283352ed5
57. Cohen C, Nieto-Cisneros L, Zala C, Fessel WJ, Gonzalez-Garcia J, Gladysz A, McGovern R, Adler E & McLaren C. Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial. Current Medical Research and Opinion 2005 21 1683-1692. (doi:10.1185/030079905X65439
58. Calza L, Manfredi R, Colangeli V, Pocaterra D, Rosseti N, Pavoni M & Chiodo F. Efficacy and safety of atazanavir-ritonavir plus abacavir- lamivudine or tenofovir-emtricitabine in patients with hyperlipidaemia switched from a stable protease inhibitor-based regimen including one thymidine analogue. AIDS Patient Care and STDS 2009 23 691-697. (doi:10.1089/apc.2009.0039
59. Mobius U, Lubach-Ruitman M, Castro-Frenzel B, Stoll M, Esser S, Voigt E, Christensen S, Rump JA, Fatkenheuer G, Behrens GM et al. Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia. Journal of Acquired Immune Deficiency Syndromes 2005 39 174-180.
60. Sension M, Andrade Neto JL, Grinsztejn B, Molina JM, Zavala I, Gonzalez-Garcia J, Donnelly A, Phiri P, Ledesma E & McGrath D. Improvement in lipid profiles in antiretroviral-experienced HIVpositive patients with hyperlipidemia after a switch to unboosted atazanavir. Journal of Acquired Immune Deficiency Syndromes 2009 51 153-162. (doi:10.1097/QAI.0b013e3181a5701c
61. Mallolas J, Podzamczer D, Milinkovic A, Domingo P, Clotet B, Ribera E, Gutierrez F, Knobel H, Cosin J, Ferrer E et al. Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study. Journal of Acquired Immune Deficiency Syndromes 2009 51 29-36. (doi:10.1097/QAI. 0b013e31819a226f
62. Gatell J, Salmon-Ceron D, Lazzarin A, Van Wijngaerden E, Antunes F, Leen C, Horban A, Wirtz V, Odeshoo L, Van den Dungen M et al. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Clinical Infectious Diseases 2007 44 1484-1492. (doi:10.1086/517497
63. van Vonderen MG, Gras L, Wit F, Brinkman K, van der Ende ME, Hoepelman AI, de Wolf F & Reiss P. Baseline lipid levels rather than the presence of reported body shape changes determine the degree of improvement in lipid levels after switching to atazanavir. HIV Clinical Trials 2009 10 168-180. (doi:10.1310/hct1003-168
64. Monforte A, Reiss P, Ryom L, El-Sadr W, Dabis F, DeWit S, Worm SW, Law MG, Weber R, Kirk O et al. Atazanavir is not associated with an increased risk of cardio-or cerebrovascular disease events. AIDS 2013 27 407-415. (doi:10.1097/QAD.0b013e32835b2ef1
65. Kumar PN, Salvato P, Lamarca A, Dejesus E, Patel P, McClernon D, Florance A & Shaefer MS. A randomized, controlled trial of initial antiretroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study). AIDS Research and Therapy 2009 6 3. (doi:10.1186/1742-6405-6-3
66. Vrouenraets SM, Wit FW, Fernandez Garcia E, Moyle GJ, Jackson AG, Allavena C, Raffi F, Jayaweera DT, Mauss S, Katlama C et al. Randomized comparison ofmetabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naive HIV-1-infected patients. HIV Medicine 2011 12 620-631. (doi:10.1111/j.1468-1293.2011.00941.x
67. Gyalrong-Steur M, Bogner JR & Seybold U. Changes in lipid profiles after switching to a protease inhibitor-containing cART - unfavourable effect of fosamprenavir in obese patients. European Journal of Medical Research 2011 16 85-92. (doi:10.1186/2047-783X-16-2-85
68. Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, Moyle G, Mancini M, Percival L, Yang R et al. Oncedaily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008 372 646-655. (doi:10. 1016/S0140-6736(08)61081-8
69. Kozal MJ, Lupo S, DeJesus E, Molina JM, McDonald C, Raffi F, Benetucci J, Mancini M, Yang R, Wirtz V et al. A nucleoside-and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naive HIV-infected patients: SPARTAN study results. HIV Clinical Trials 2012 13 119-130. (doi:10.1310/hct1303-119
70. Podzamczer D, Andrade-Villanueva J, Clotet B, Taylor S, Rockstroh JK, Reiss P, Domingo P, Gellermann HJ, de Rossi L, Cairns V et al. Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naive HIV-1-infected patients (the ARTEN study). HIV Medicine 2011 12 374-382. (doi:10.1111/j.1468- 1293.2011.00917.x
71. Hileman C, Longenecker C, Carman T,Milne G, Labbato DE, Storer N, White C & McComsey G. Relationship between total bilirubin and endothelial function, inflammation and oxidative stress in HIVinfected adults on stable antiretroviral therapy. HIV Medicine 2012 13 609-616. (doi:10.1111/j.1468-1293. 2012.01026.x
72. Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS & Humphreys WG. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metabolism and Disposition 2005 33 1729-1739. (doi:10.1124/dmd.105.005447
73. Flammer AJ, Vo NT, Ledergerber B, Hermann F, Gamperli A, Huttner A, Evison J, Baumgartner I, Cavassini M, Hayoz D et al. Effect of atazanavir versus other protease inhibitor-containing antiretroviral therapy on endothelial function in HIV-infected persons: randomised controlled trial. Heart 2009 95 385-390. (doi:10.1136/hrt.2007. 137646
74. ColafigliM, Di Giambenedetto S, Bracciale L, Tamburrini E, Cauda R & De Luca A. Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen. HIVMedicine 2008 9 172-179. (doi:10.1111/j.1468-1293.2007.00541.x
75. Young B, Squires KE, Ross LL, Santiago L, Sloan LM, Zhao HH, Wine BC, Pakes GE, Margolis DA & Shaefer MS. Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES. AIDS Research and Human Retroviruses 2013 29 350-358. (doi:10.1089/AID.2012.0278
76. de Saint-Martin L, Bressollette L, Perfezou P, Bellein V, Ansart S, Vallet S & Pasquier E. Impact of atazanavir-based HAART regimen on the carotid intima-media thickness of HIV-infected persons: a comparative prospective cohort. AIDS 2010 24 2797-2801. (doi:10. 1097/QAD.0b013e328340a21f
77. Busti AJ, Bedimo R, Margolis DM & Hardin DS. Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir/ritonavir. Journal of Investigative Medicine 2008 56 539-544. (doi:10.231/JIM. 0b013e3181641b26
78. Guffanti M, Caumo A, Galli L, Bigoloni A, Galli A, Dagba G, Danise A, Luzi L, Lazzarin A & Castagna A. Switching to unboosted atazanavir improves glucose tolerance in highly pretreated HIV-1 infected subjects. European Journal of Endocrinology 2007 156 503-509. (doi:10.1530/EJE-06-0648
79. Stanley TL, Joy T, Hadigan CM, Liebau JG, Makimura H, Chen CY, Thomas BJ, Weise SB, Robbins GK & Grinspoon SK. Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients. AIDS 2009 23 1349-1357. (doi:10.1097/QAD.0b013e32832ba904
80. Haerter G, Manfras BJ, Mueller M, Kern P & Trein A. Regression of lipodystrophy in HIV-infected patients under therapy with the new protease inhibitor atazanavir. AIDS 2004 18 952-955. (doi:10.1097/00002030-200404090- 00016
81. McComsey G, Rightmire A, Wirtz V, Yang R, MathewM& McGrath D. Changes in body composition with ritonavir-boosted and unboosted atazanavir treatment in combination with Lamivudine and Stavudine: a 96-week randomized, controlled study. Clinical Infectious Diseases 2009 48 1323-1326. (doi:10.1086/597776
82. Jemsek JG, Arathoon E, Arlotti M, Perez C, Sosa N, Pokrovskiy V, Thiry A, Soccodato M, Noor MA & Giordano M. Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients. Clinical Infectious Diseases 2006 42 273-280. (doi:10.1086/498505
83. Moyle GJ, Andrade-Villanueva J, Girard PM, Antinori A, Salvato P, Bogner JR, Hay P, Santos J, Astier L, Pans M et al. A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposity. Antiviral Therapy 2012 17 689-700. (doi:10.3851/IMP2083
84. Martinez E, Gonzalez-Cordon A, Ferrer E, Domingo P, Negredo E, Gutierrez F, Portilla J, Curran A, Podzamczer D, Murillas J et al. Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir. HIV Medicine 2014. In press. (doi:10.1111/hiv.12121
85. Ortiz R, Dejesus E, Khanlou H, Voronin E, van Lunzen J, Andrade-Villanueva J, Fourie J, De Meyer S, De Pauw M, Lefebvre E et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008 22 1389-1397. (doi:10.1097/QAD.0b013e32830285fb
86. Arathoon E, Schneider S, Baraldi E, Lim PL, Opravil M, Van De Casteele T & Lavreys L. Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on metabolic parameters in treatment-naive HIV-1-infected patients at week 96: ARTEMIS. International Journal of STD & AIDS 2013 24 12-17. (doi:10.1258/ijsa.2012.012120
87. Mills AM, Nelson M, Jayaweera D, Ruxrungtham K, Cassetti I, Girard PM, Workman C, Dierynck I, Sekar V, Abeele CV et al. Oncedaily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS 2009 23 1679-1688. (doi:10.1097/QAD.0b013e32832d7350
88. Aberg JA, Tebas P, Overton ET, Gupta SK, Sax PE, Landay A, Falcon R, Ryan R & De La Rosa G.Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS Research and Human Retroviruses 2012 28 1184-1195. (doi:10.1089/aid.2011.0327
89. Arasteh K, Yeni P, Pozniak A, Grinsztejn B, Jayaweera D, Roberts A, Hoy J, De Meyer S, Vangeneugden T & Tomaka F. Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96. Antiviral Therapy 2009 14 859-864. (doi:10.3851/IMP1301
90. Madruga JV, Berger D, McMurchie M, Suter F, Banhegyi D, Ruxrungtham K, Norris D, Lefebvre E, de Bethune MP, Tomaka F et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIVinfected patients in TITAN: a randomised controlled phase III trial. Lancet 2007 370 49-58. (doi:10.1016/S0140-6736(07)61049-6
91. Guaraldi G, Zona S, Cossarizza A, Vernacotola L, Carli F, Lattanzi A, Beghetto B, Orlando G, De Biasi S, Termini R et al. Randomized trial to evaluate cardiometabolic and endothelial function in patients with plasma HIV-1 RNA suppression switching to darunavir/ritonavir with or without nucleoside analogues. HIV Clinical Trials 2013 14 140-148. (doi:10.1310/hct1404-140
92. Currier JS, Martorell C, Osiyemi O, Yin MT, Ryan R, De La Rosa G & Mrus J. Effects of darunavir/ritonavir-based therapy on metabolic and anthropometric parameters in women and men over 48 weeks. AIDS Patient Care and STDS 2011 25 333-340. (doi:10.1089/apc.2010.0386
93. Ucciferri C, Falasca K, Vignale F, Di Nicola M, Pizzigallo E & Vecchiet J. Improved metabolic profile after switch to darunavir/ritonavir in HIV positive patients previously on protease inhibitor therapy. Journal of Medical Virology 2013 85 755-759. (doi:10.1002/jmv.23543
94. Valantin MA, Kolta S, Flandre P, Algarte Genin M, Meynard JL, Ponscarme D, Slama L, Cuzin L, de Kerviler E, Inaoui R et al. Body fat distribution in HIV-infected patients treated for weeks with darunavir/ritonavir monotherapy versus darunavir/ritonavir plus nucleoside reverse transcriptase inhibitors: the MONOI-ANRS136 substudy. HIV Medicine 2012 13 505-515. (doi:10.1111/j.1468-1293. 2012.01004.x
95. Sax PE, DeJesus E, Mills A, Zolopa A, Cohen C, Wohl D, Gallant JE, Liu HC, Zhong L, Yale K et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012 379 2439-2448. (doi:10.1016/S0140-6736(12)60917-9
96. Tashima KT, Bausserman L, Alt EN, Aznar E & Flanigan TP. Lipid changes in patients initiating efavirenz-and indinavir-based antiretroviral regimens. HIV Clinical Trials 2003 4 29-36. (doi:10.1310/F2V7-3R46-VX6J-241R
97. Rockstroh JK, DeJesus E, Henry K, Molina JM, Gathe J, Ramanathan S, Wei X, Plummer A, Abram M, Cheng AK et al. A randomized, doubleblind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results. Journal of Acquired Immune Deficiency Syndromes 2013 62 483-486. (doi:10.1097/QAI. 0b013e318286415c
98. Gotti D, Cesana BM, Albini L, Calabresi A, Izzo I, Foca E, Motta D, Bellagamba R, Fezza R, Narciso P et al. Increase in standard cholesterol and large HDL particle subclasses in antiretroviral-naive patients prescribed efavirenz compared to atazanavir/ritonavir. HIV Clinical Trials 2012 13 245-255. (doi:10.1310/hct1305-245
99. McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Melbourne K, Ha B, Brown TT, Bloom A, Fedarko N et al. Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir. AIDS 2012 26 1371-1385. (doi:10.1097/QAD.0b013e328354f4fb
100. Miro J MC, Guardo A, Lozano F, Ferrer E, Domingo P, Curran A, Clotet B, PlanaM, Gatell J & the Advanz-3 Investigators. Effect of cART on bacterial transloaction, inflammation, coagulation, and immune activation markers in advanced ARV-naive patients (!100 CD4C cell/mm3). 19th Conference on Retroviruses and Opportunistic Infections, Seattle, March 5-8, 2012, Abstract 276.
101. McComsey GA, Daar ES, O'Riordan M, Collier AC, Kosmiski L, Santana JL, Fichtenbaum CJ, Fink H, Sax PE, Libutti DE et al. Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir- ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202. Journal of Infectious Diseases 2013 207 604-611. (doi:10.1093/infdis/jis720
102. Apostolova N, Gomez-Sucerquia LJ, Gortat A, Blas-Garcia A & Esplugues JV. Autophagy as a rescue mechanism in efavirenz-induced mitochondrial dysfunction: a lesson from hepatic cells. Autophagy 2011 7 1402-1404. (doi:10.4161/auto.7.11.17653
103. Gomez-Sucerquia LJ, Blas-Garcia A, Marti-Cabrera M, Esplugues JV & Apostolova N. Profile of stress and toxicity gene expression in human hepatic cells treated with Efavirenz. Antiviral Research 2012 94 232-241. (doi:10.1016/j.antiviral.2012.04.003
104. Erlandson K KD, Tierney C, Sax P, Daar E, Tebas P, Melbourne K, Ha B, Jahed N & McComsey G. Change in lean body mass and association with bone mineral density change in subjects randomized to abacavir/lamivudine or tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz: ACTG A5224s. 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, March 3-6, 2013. Abstract 825.
105. Pozniak AL, Gallant JE, DeJesus E, Arribas JR, Gazzard B, Campo RE, Chen SS, McColl D, Enejosa J, Toole JJ et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes - a 96-week analysis. Journal of Acquired Immune Deficiency Syndromes 2006 43 535-540.
106. Palella F TP, Gazzard B, Ruane P, Shamblaw D, Flamm J, Fisher M, van Lunzen J, Ebrahimi R, White K, Guyer B, et al. SPIRIT study: switching to emtricitabine/rilpivirine/tenofovir df single-tablet regimen from a ritonavir-boosted protease inhibitor and two nucleosie reverse transcriptase inhibitors maintains HIV suppression and improves seru. 19th International AIDS Conference, July 22-27, 2012, Washington DC, Abstract TUAB0104.
107. Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, Supparatpinyo K, Walmsley S, Crauwels H, Rimsky LT et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase randomised doubleblind active-controlled trial. Lancet 2011 378 238-246. (doi:10.1016/S0140-6736(11)60936-7
108. Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA, Ruxrungtham K, Wu H, Zorrilla C, Crauwels H, Rimsky LT et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011 378 229-237. (doi:10.1016/S0140- 6736(11)60983-5
109. Molina JM, Clumeck N, Orkin C, Rimsky L, Vanveggel S & Stevens M. Week 96 analysis of rilpivirine or efavirenz in HIV-1-infected patients with baseline viral load !/Z100 000 copies/mL in the pooled ECHO and THRIVE phase 3, randomized, double-blind trials. HIV Medicine 2013 15 57-62. (doi:10.1111/hiv.12071
110. Molina JM, Clumeck N, Redant K, Rimsky L, Vanveggel S & StevensM. Rilpivirine vs. efavirenz in HIV-1 patients with baseline viral load 100,000 copies/ml or less: week 48 phase III analysis. AIDS 2013 27 889-897. (doi:10.1097/QAD.0b013e32835e1554
111. Tebas PHK, Nelson M, Reynes J, Ruxrungtham K, Sierra-Madero J, Vanveggel S, Deckx H & Boven K. Results from the pooled DEXA substudies of the double-blind, randomised, Phase III trials comparing rilpivirine (RPV, TMC278) versus efavirenz (EFV) in treatment-naive, HIV-1-infected adults. Antiviral Therapy 2011 16 A19.
112. Diaz-Delfin J, Domingo P, Mateo MG, Gutierrez Mdel M, Domingo JC, Giralt M & Villarroya F. Effects of rilpivirine on human adipocyte differentiation, gene expression, and release of adipokines and cytokines. Antimicrobial Agents and Chemotherapy 2012 56 3369-3375. (doi:10.1128/AAC.00104-12
113. Smith RL, de Boer R, Brul S, Budovskaya Y & van Spek H. Premature and accelerated aging: HIV or HAART? Frontiers in Genetics 2012 3 328. (doi:10.3389/fgene.2012.00328)